209 related articles for article (PubMed ID: 35289062)
1. Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism.
Frischmuth T; Hindberg K; Aukrust P; Ueland T; Braekkan SK; Hansen JB; Morelli VM
J Thromb Haemost; 2022 Jul; 20(7):1618-1626. PubMed ID: 35289062
[TBL] [Abstract][Full Text] [Related]
2. Elevated plasma D-dimer levels are associated with risk of future incident venous thromboembolism.
Hansen ES; Rinde FB; Edvardsen MS; Hindberg K; Latysheva N; Aukrust P; Ueland T; Michelsen AE; Hansen JB; Brækkan SK; Morelli VM
Thromb Res; 2021 Dec; 208():121-126. PubMed ID: 34763296
[TBL] [Abstract][Full Text] [Related]
3. Plasma Levels of Leptin and Risk of Future Incident Venous Thromboembolism.
Frischmuth T; Hindberg K; Aukrust P; Ueland T; Brækkan SK; Hansen JB; Morelli VM
Thromb Haemost; 2022 Apr; 122(4):560-569. PubMed ID: 34264516
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism.
Edvardsen MS; Hindberg K; Hansen ES; Morelli VM; Ueland T; Aukrust P; Brækkan SK; Evensen LH; Hansen JB
Blood Adv; 2021 Jan; 5(1):224-232. PubMed ID: 33570640
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of growth differentiation factor 15 are associated with future risk of venous thromboembolism.
Hansen ES; Hindberg K; Latysheva N; Aukrust P; Ueland T; Hansen JB; Brækkan SK; Morelli VM;
Blood; 2020 Oct; 136(16):1863-1870. PubMed ID: 32645137
[TBL] [Abstract][Full Text] [Related]
6. The Risk of Incident Venous Thromboembolism Attributed to Overweight and Obesity: The Tromsø Study.
Frischmuth T; Tøndel BG; Brækkan SK; Hansen JB; Morelli VM
Thromb Haemost; 2024 Mar; 124(3):239-249. PubMed ID: 37549694
[TBL] [Abstract][Full Text] [Related]
7. Elevated plasma concentration of complement factor C5 is associated with risk of future venous thromboembolism.
Skjeflo EW; Brækkan SK; Ludviksen JK; Snir O; Hindberg K; Mollnes TE; Hansen JB
Blood; 2021 Nov; 138(21):2129-2137. PubMed ID: 34339498
[TBL] [Abstract][Full Text] [Related]
8. Impact of the von Willebrand factor-ADAMTS-13 axis on the risk of future venous thromboembolism.
Edvardsen MS; Hansen ES; Ueland T; Aukrust P; Brækkan SK; Morelli VM; Hansen JB
J Thromb Haemost; 2023 May; 21(5):1227-1237. PubMed ID: 36736832
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of platelet-derived microvesicles are associated with risk of future venous thromboembolism.
Snir O; Wilsgård L; Latysheva N; Wahlund CJE; Braekkan SK; Hindberg K; Hansen JB
J Thromb Haemost; 2022 Apr; 20(4):899-908. PubMed ID: 35000275
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of P-selectin and future risk of incident venous thromboembolism.
Swamy S; Ueland T; Hansen JB; Snir O; Brækkan SK
J Thromb Haemost; 2023 Sep; 21(9):2451-2460. PubMed ID: 37182696
[TBL] [Abstract][Full Text] [Related]
11. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis.
Wang J; Wang C; Chen N; Shu C; Guo X; He Y; Zhou Y
Thromb Res; 2014 Dec; 134(6):1241-8. PubMed ID: 25450536
[TBL] [Abstract][Full Text] [Related]
12. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
Bollen L; Peetermans M; Peeters M; Van Steen K; Hoylaerts MF; Declerck PJ; Verhamme P; Gils A
Thromb Res; 2014 Nov; 134(5):1097-102. PubMed ID: 25193405
[TBL] [Abstract][Full Text] [Related]
13. C-reactive protein, obesity, and the risk of arterial and venous thrombosis.
Horvei LD; Grimnes G; Hindberg K; Mathiesen EB; Njølstad I; Wilsgaard T; Brox J; Braekkan SK; Hansen JB
J Thromb Haemost; 2016 Aug; 14(8):1561-71. PubMed ID: 27208592
[TBL] [Abstract][Full Text] [Related]
14. Complement activation assessed by the plasma terminal complement complex and future risk of venous thromboembolism.
Høiland II; Liang RA; Braekkan SK; Pettersen K; Ludviksen JK; Latysheva N; Snir O; Ueland T; Hindberg K; Mollnes TE; Hansen JB
J Thromb Haemost; 2019 Jun; 17(6):934-943. PubMed ID: 30920726
[TBL] [Abstract][Full Text] [Related]
15. Combined effect of high factor VIII levels and high mean platelet volume on the risk of future incident venous thromboembolism.
Hansen ES; Edvardsen MS; Aukrust P; Ueland T; Hansen JB; Brækkan SK; Morelli VM
J Thromb Haemost; 2023 Oct; 21(10):2844-2853. PubMed ID: 37393000
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of mannose-binding lectin and future risk of venous thromboembolism.
Liang RA; Høiland II; Ueland T; Aukrust P; Snir O; Hindberg K; Braekkan SK; Garred P; Mollnes TE; Hansen JB
J Thromb Haemost; 2019 Oct; 17(10):1661-1669. PubMed ID: 31220397
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence.
Sundquist K; Wang X; Svensson PJ; Sundquist J; Hedelius A; Larsson Lönn S; Zöller B; Memon AA
Thromb Haemost; 2015 Nov; 114(6):1156-64. PubMed ID: 26245493
[TBL] [Abstract][Full Text] [Related]
18. Serum C-reactive protein increases the risk of venous thromboembolism: a prospective study and meta-analysis of published prospective evidence.
Kunutsor SK; Seidu S; Blom AW; Khunti K; Laukkanen JA
Eur J Epidemiol; 2017 Aug; 32(8):657-667. PubMed ID: 28718029
[TBL] [Abstract][Full Text] [Related]
19. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
20. High Levels of Complement Activating Enzyme MASP-2 Are Associated With the Risk of Future Incident Venous Thromboembolism.
Damoah CE; Snir O; Hindberg K; Garred P; Ludviksen JK; Brækkan SK; Morelli VM; Mollnes TE; Hansen JB;
Arterioscler Thromb Vasc Biol; 2022 Sep; 42(9):1186-1197. PubMed ID: 35861070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
